Q-omics provides the consensus-scored IL20RA profile across patient tissues and cancer cell-line models. IL20RA expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IL20RA is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, IL20RA RNA expression shows 15,879 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where IL20RA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL20RA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL20RA survival associations across molecular data types. IL20RA RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL20RA RNA expression–survival associations across cancer types. High IL20RA expression shows unfavorable associations in KIRC, SKCM and LUAD, but favorable associations in UCEC, HNSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IL20RA RNA expression.
This table summarizes IL20RA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for IL20RA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL20RA shows lower tumor expression in KIRC, LUAD and THCA and higher tumor expression in COAD, STAD and BLCA. The COAD box plot shows higher IL20RA RNA expression in tumor versus normal tissue (log2 FC = +1.346, t-test p < 0.001).
This table shows molecular features associated with IL20RA in patient tissues and cancer cell lines. In patient samples, IL20RA shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL20RA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and URINARY_TRACT.
